Its expression predicts poor overall patient survival in breast and pancreatic cancer patients26,27 and is linked to increased resistance to therapy28–32, indicating that targeting Axl may represent a novel therapeutic approach for cancer treatment. This evidence concerns the gene AXL and cancer.